GRI Bio increases ATM offering capacity by $1.76M after selling $4.55M previously

GRI Bio, Inc.

Filed prospectus supplement to increase maximum shares issuable under ATM to $1,758,934.
Previously sold ~$4,546,137 in shares under May 2024 Sales Agreement with H.C. Wainwright.
Total potential gross proceeds under the ATM program now approximately $6.3 million.
Shares to be sold at market prices; proceeds for general corporate purposes.
Legal opinion on share issuance from Mintz Levin attached as Exhibit 5.1.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.